Literature DB >> 19303974

Metformin suppresses high glucose-induced poly(adenosine diphosphate-ribose) polymerase overactivation in aortic endothelial cells.

Meriem Mahrouf-Yorgov1, Nicolas Marie, Didier Borderie, Raja Djelidi, Dominique Bonnefont-Rousselot, Alain Legrand, Jean-Louis Beaudeux, Jacqueline Peynet.   

Abstract

Overactivation of poly(adenosine diphosphate-ribose) polymerase (PARP), an enzyme involved in cellular response to DNA injury resulting from oxidative and nitrosative stress, is considered to play a key role in the pathogenesis of diabetes complications by promoting numerous vascular dysfunctions. In this study, we examined the ability of metformin, which was reported to possess intrinsic vasculoprotective properties independently of its antihyperglycemic effects, to inhibit PARP activation induced by high glucose concentrations in bovine aortic endothelial cells; and we investigated the potential mechanisms involved in this inhibition. The PARP activity was measured by cellular enzyme-linked immuno-specific assay (CELISA) method; cell poly(ribosyl)ated protein polymer accumulation was evaluated by immunofluorescence. Peroxynitrite anion productions were determined using dihydrorhodamine 123 fluoroprobe; and expression of p47phox subunit of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase was analyzed by Western blot in the absence and presence of protein kinase C and NAD(P)H oxidase inhibitors (calphostin and diphenyleneiodonium chloride, respectively). Our data showed that a therapeutically relevant concentration of metformin (5.10(-5) mol/L) was able to abolish PARP activation, to reduce poly(ribosyl)ated protein polymer accumulation, to decrease intracellular peroxynitrite anion level, and to reverse the overexpression of p47phox in bovine aortic endothelial cells stimulated by 25 mmol/L glucose in a similar manner to that of calphostin or diphenyleneiodonium chloride. Taken together, these results suggest that metformin could inhibit glucose-induced PARP activation through blockade of a protein kinase C-dependent NAD(P)H oxidase activation pathway. We propose that some of the beneficial effects of metformin on vascular endothelial cell functions in diabetes may be related to its inhibitory effect on PARP overactivation and its deleterious consequences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303974     DOI: 10.1016/j.metabol.2008.11.012

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Nanoformulation of Leonotis leonurus to improve its bioavailability as a potential antidiabetic drug.

Authors:  Frank Odei-Addo; Ranjita Shegokar; Rainer H Müller; R-A Levendal; Carminita Frost
Journal:  3 Biotech       Date:  2017-09-23       Impact factor: 2.406

Review 2.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

3.  Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts.

Authors:  Jian Bai; Na Zhang; Ying Hua; Bingjian Wang; Lin Ling; Albert Ferro; Biao Xu
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

Review 4.  Metformin as a cellular protector; a synoptic view of modern evidences.

Authors:  Nicolas Wiernsperger
Journal:  J Nephropharmacol       Date:  2015-01-01

Review 5.  A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function.

Authors:  K G Kheniser; S R Kashyap; T Kasumov
Journal:  Obes Sci Pract       Date:  2019-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.